{Reference Type}: Review
{Title}: HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018-2021): A Review of Criticism and Concerns in Comments From Regulators.
{Author}: Comerford E;Norcross L;Sasane M;Zheng Y;Gnanasakthy A;
{Journal}: J Natl Compr Canc Netw
{Volume}: 22
{Issue}: 2
{Year}: 2024 Apr 5
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2023.7146